Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Blood

Volumn 112, Issue 12, 2008, Pages 4445-4451

  Wang, Michael ^a   Dimopoulos, Meletios A ^b   Chen, Christine ^c   Cibeira, M Teresa ^d   Attal, Michel ^e   Spencer, Andrew ^f   Rajkumar, S Vincent ^g   Yu, Zhinuan ^h   Olesnyckyj, Marta ^h   Zeldis, Jerome B ^h   Knight, Robert D ^h   Weber, Donna M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CHU PURPAN   (France)

^f ALFRED HOSPITAL   (Australia)

^g MAYO CLINIC CANCER CENTER   (United States)

^h CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PLACEBO; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; EVALUATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 58149384555     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-141614     Document Type: Article

References (21)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111: 2516-2520.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
4. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005;32(suppl 5):S24-S30.
5. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
6. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
7. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
8. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99: 4525-4530.
9. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100:3063-3067.
10. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108: 3458-3464.
11. Anderson KC. Lenalidomide and thalidomide: mechanisms of action: similarities and differences. Semin Hematol. 2005;42(suppl 4):S3-S8.
12. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42:1612-1622.
13. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179-1184.
14. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357:2133-2142.
15. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357:2123-2132.
16. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
17. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
18. Stadtmauer E, Weber D, Dimopoulos M, et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma. Blood. 2006;108: Abstract 3552.
19. Wang M, Knight R, Dimopoulos M, et al. Comparison of lenatidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma. J Clin Oncol. 2006; 24: Abstract 7522.
20. Wang M, Knight R, Dimopoulos M, et al. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood. 2006;108: Abstract 3553.
21. Wang M, Knight R, Dimopoulos M, et al. Effect of Lea/Der in MM despite thal resistance. Haematologica. 2007;92: Abstract PO-662.